Ann: Positive BTX 1702 Phase 1b/2 Clinical Study for Rosacea, page-97

I think he's carefully worded - he says BOT do have enough money in the bank to get SB over the line (read - approved) and 'commence' commercialization, but whether BOT can sustain commercialization/manufacture/supply without another CR is another question, and he does say BOT will consider their options at that point. How much cash do you think they need to commercialize considering BOT have said they are looking to contract out production (so no capital purchases)? Maybe they can do a deal with the manufacturer that negates a CR?